Shares fell more than 66% Monday morning, which analysts suspect is due to investors seeing the data as not competitive with ...
The deal gives Argenx a drug prospect aimed at the protein target CD122, an approach that’s recently gained traction among ...
Capricor shares lost much of their value ahead of a high-stakes advisory committee meeting. Elsewhere, Ying Huang’s resignation extended a stock slide for Legend and AstraZeneca disclosed more ...
Most recently the leader of buzzy startup Tessera Therapeutics, Severino will look to improve the fortunes of a company ...
In a victory for Robert F. Kennedy Jr.’s “MAHA” agenda, panelists narrowly recommended broader use of four peptides despite a ...
The startup is the first gene editing company to price an IPO in more than two years, though it banked far less than most ...
The new findings position Lilly to file an application for the highly anticipated medicine, but also leave some questions ...
The lawsuit follows a cease-and-desist request and argues Lilly is using “deceptive” ads to claim its GLP-1 products are ...
The decision to no longer seek approval of amlitelimab is the latest setback for a treatment once hailed as a future ...
The acquisition, which involves a concurrent licensing deal with startup Mirador, gives Jasper a chance to rebound from ...
The clearance is GSK’s first for a lung cancer medicine and the latest step forward in a yearslong push by the British ...
Analysts expect new details on the lead-up to the deal “are likely to reignite” investor scrutiny that Vertex overpaid in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results